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Objectives: To describe our experience with a coronavirus disease 2019 (COVID-19)
outbreak within a large rheumatology department early in the pandemic.
Methods: Symptomatic and asymptomatic healthcare workers (HCWs) had a
naso-oropharyngeal swab for detection of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and were followed clinically. Reverse transcription
polymerase-chain reaction (RT-PCR) was repeated to document cure, and serological
response was assessed. Patients with risk contacts within the department in the 14
days preceding the outbreak were screened for COVID-19 symptoms.
Results: 14/34 HCWs (41%; 40 ± 14 years, 71% female) tested positive for
SARS-CoV-2, and 11/34 (32%) developed symptoms but were RT-PCR-negative. Half
of RT-PCR-positive HCWs did not report fever, cough, or dyspnea before testing, which
were absent in 3/14 cases (21%). Mild disease prevailed (79%), but 3 HCWs had
moderate disease requiring further assessment, which excluded severe complications.
Nevertheless, symptom duration (28 ± 18 days), viral shedding (31 ± 10 days
post-symptom onset, range 15–51), and work absence (29 ± 28 days) were prolonged.
13/14 (93%) of RT-PCR-positive and none of the RT-PCR-negative HCWs had a positive
humoral response Higher IgG indexes were observed in individuals over 50 years of
age (14.5 ± 7.7 vs. 5.0 ± 4.4, p = 0.012). Of 617 rheumatic patients, 8 (1.3%)
developed COVID-19 symptoms (1/8 hospitalization, 8/8 complete recovery), following
a consultation/procedure with an asymptomatic (7/8) or mildly symptomatic (1/8) HCW.
Conclusions: A COVID-19 outbreak can occur among HCWs and rheumatic patients,
swiftly spreading over the presymptomatic stage. Mild disease without typical symptoms
should be recognized and may evolve with delayed viral shedding, prolonged recovery,
and adequate immune response in most individuals.
Keywords: COVID-19, rheumatology practice, rheumatic patients, healthcare workers (HCW), presymptomatic
transmission
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INTRODUCTION
Following the initial descriptions in early January 2020 of a novel
form of severe pneumonia in patients from Wuhan, China (1–
4), the coronavirus disease 2019 (COVID-19) quickly spread at
a global level. On January 30, the World Health Organization
declared it a public health emergency of international concern
(5), and it was subsequently updated to a pandemic on March
11 (6). After the first reported case in Portugal (March 2),
exponential growth led to the institution of major restrictive
measures (7).
Consistently high infection rates among healthcare workers
(HCWs) have been reported in several hard-hit countries, such
as China (8, 9), Italy (10), Spain (11), and the United States
(12), despite adequate safety measures (13). One possibility is
that in-hospital transmission among patients and HCWs might
be a key form of contagion (9, 14, 15). This is particularly
relevant given the transmission dynamics of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), whereby
presymptomatic/asymptomatic contamination is likely to play a
major role in disease spreading (14–19).
In the early days of the pandemic, most focus was given
to severe clinical pictures (2, 8, 9, 20), and reports on mild
or asymptomatic disease were scarce (21, 22). This may
have contributed to an initial oversight of more general, less
severe manifestations, such as upper respiratory and digestive
symptoms (23). These milder disease forms might be easily
undervalued, including by HCWs responding to the pandemic.
In healthcare facilities, this may facilitate the generalized
spread among HCWs, who can serve as disease-transmission
agents (9, 14–16). This fact may be particularly relevant
in outpatient-oriented departments with a high volume of
clinical activity (e.g., rheumatology). In addition, rheumatology
practice requires daily close physical contact with patients with
rheumatic and musculoskeletal diseases (RMDs), who are often
immunosuppressed and have an increased overall infectious risk.
In the present report, we aim to describe our experience with
a COVID-19 outbreak within our department, upon the initial
weeks of the pandemic, highlighting clinical, virological, and
immunological outcomes of HCWs and RMD patients.
MATERIALS AND METHODS
Outbreak Characterization
Over the week of March 9–15, 2020, several HCWs of the
rheumatology department of Centro Hospitalar Universitário
Lisboa Norte (CHULN) developed mild symptoms compatible
with COVID-19. All staff (symptomatic/asymptomatic)
underwent screening for SARS-CoV-2 on March 15–16. Double
naso-oropharyngeal swabs were obtained, and samples were
tested for SARS-CoV-2 by reverse transcription-polymerase
chain reaction (RT-PCR; cobas R©SARS-CoV-2 kit, cobas R©6800
System, Roche Diagnostics, USA). All the confirmed and
suspected cases were quarantined and referred to public health
authorities. Daily remote clinical monitoring of HCWs was
conducted by 2 asymptomatic rheumatologists in conjunction
with public health and occupational medicine specialists.
Testing of HCWs was repeated (i) 7–14 days after the first
negative test in subjects with persisting symptoms and (ii) 5–7
days following the resolution of fever and improvement in
respiratory symptoms in confirmed cases (24). Two consecutive
negative tests were required to confirm viral shedding cessation
and allow return to work (25). Immunological response to
SARS-CoV-2 was evaluated by chemiluminescent immunoassay
(MAGLUMI R©800 CLIA System, MAGLUMI R©2019-nCoV
(SARS-CoV-2) IgM/IgG-kits, Snibe Co., Ltd., China) in all
HCWs, following symptom resolution and double-negative
RT-PCR in confirmed cases.
We contacted patients observed during the previous 2 weeks
in the day-care unit, outpatient clinic, and procedures room
who had possible contacts with confirmed RT-PCR-positive
HCWs. Each patient was screened for suggestive symptoms
and requested to remain in isolation for 14 days post-contact
with the department. Patients with symptoms compatible with
COVID-19 were referred to the national health system hotline
and signaled to health authorities, who had also received the list
of screened patients.
Study Procedures
All HCWs of the rheumatology department who were
working during March 2–13, 2020, including visiting fellows,
were invited to participate in this study. A standardized
questionnaire was administered to collect demographic data,
symptom characterization, disease course and outcome,
treatment, comorbidities, and concomitant therapy. Results
of laboratory and imaging studies performed, including RT-
PCR and IgG/IgM for SARS-CoV-2 were reviewed. Disease
course was classified as mild, moderate (requiring physical
examination and laboratory/imaging studies), or severe
(requiring hospitalization). Moreover, patients observed in the
department between March 2–13 who developed symptoms
suggestive of COVID-19 had an appointment scheduled, upon
definite resolution, for clinical observation. The same data
were collected as for HCWs, in addition to variables related to
the RMD and associated treatment. Patients observed in the
period of interest who did not develop COVID-19 symptoms
or did so outside the 14-day window after the last contact with
the department, were excluded. All study participants signed
a study-specific informed consent. This study was approved
by the Lisbon Academic Medical Center Ethics Committee
(reference 171/20).
Statistical Analysis
Demographic and clinical characteristics were presented as
frequency, mean ± standard deviation, or median [interquartile
range (IQR)] as applicable. Comparison of continuous variables
between HCW groups was performed using Kruskal–Wallis
(3 groups) or Mann–Whitney U-test (2 groups). Categorical
variables were compared using Chi-square or Fisher’s exact test.
Agreement between RT-PCR and serological tests was done
using Kappa statistic. Pearson correlation was applied to study
the relation of IgG humoral response and clinical variables.
Statistical analyses were performed using Stata-12.1 for Mac
(StataCorp, College Station, USA) and GraphPad-Prism-7 for
MacOS (GraphPad Software, USA). P-value was considered
significant at p < 0.05.
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RESULTS
Clinical and Virological Course of HCWs
A total of 25/34 HCWs (17 rheumatologists, 8 residents, 4 visiting
fellows, 1 nurse, 1 health aid, 2 secretaries, and 1 cleaning aid)
developed symptoms suggestive of a viral infection, 14 of whom
had a positive RT-PCR for SARS-CoV-2 (Table 1, Figure 1,
Supplementary Figure 1). Ten out of 14 (71%) positive cases
were female or younger than 50 years old. Only 4/14 (29%)
subjects had a previous history of cardiovascular disease and/or
metabolic syndrome, whereas 3/14 (21%) had a diagnosis of
immune-mediated inflammatory disease (one of whom treated
with methotrexate 15 mg/week). Importantly, 5/14 (36%) HCWs
did not develop fever, which lasted ≤3 days in 4/9 (44%)
remaining cases. Cough was also absent in the same proportion
(36%). Of note, 7/14 (50%) subjects did not develop any of the
manifestations of the typical COVID-19 triad prior to the positive
RT-PCR test, which were completely missing in 3 cases (21%)
throughout the disease. In turn, milder symptoms were already
present during the week prior to the outbreak identification in
several instances. Anosmia and dysgeusia were present in over
half the cases, including 1 subject (HCW6) who did not develop
fever, cough, or dyspnea.
The majority of cases (11/14, 79%) had a benign course.
There were no hospitalizations, but 3/14 HCWs (aged 45–61
with relevant comorbidities) underwent clinical, laboratory,
and radiographic evaluation 7–12 days after symptom onset
due to persistent fever, cough, chest pain, and/or shortness
of breath (Supplementary Table 1). Lymphopenia (1/3),
thrombocytopenia (1/3), raised lactate dehydrogenase (1/3),
D-dimers (2/3), fibrinogen (2/3), and C-reactive protein (CRP;
2/3) were identified, but hypoxemia and radiographic signs of
COVID-19 pneumonia were absent. Seven subjects (50%) were
treated with hydroxychloroquine (400 mg/day, median 9 days,
range 7–14 days), and 4 received concomitant azithromycin (500
mg/day, 5 days). One HCW developed a bacterial sinus infection,
treated with amoxicillin/clavulanate. Secondary transmission to
household members was confirmed in 7/14 (50%) cases, one to 2
close relatives, all with mild disease.
Despite the favorable course of most cases, symptom duration
was prolonged (median 24.5 days, IQR 15–39, range 2–
58; Table 1, Figure 1, Supplementary Figure 1). At the end
of follow-up, 2 subjects had persistent symptoms (Figure 1,
Supplementary Figure 1). Likewise, naso-oropharyngeal RT-
PCR remained positive on average for 31 ± 10 days from
symptom onset (median 29.5 days, IQR 25–35, range 15–51;
Figure 1). This resulted in the need to repeat RT-PCR tests
frequently, with a median number of tests per positive subject of
5 (IQR 4–6, range 4–9). Of note, 8/34 (24%) of repetition tests
in completely asymptomatic subjects were positive. Yet, this was
less than in individuals who repeated testing while still showing
some symptoms (13/25, 52%, p = 0.024; Figure 1). On average,
HCWs were away from work for 29.2 ± 9.8 days (median 24.5,
IQR 23–36, range 16–51).
Eleven subjects developed various symptoms but tested
negative even upon retesting (Table 1, Figure 1). These HCWs
reported complaints of cough (55%), rhinorrhea (45%), sore
throat (82%), and other symptoms in similar frequency and
duration to confirmed cases over the same time frame. However,
fever, fatigue, malaise, headache, myalgia, anosmia, and dysgeusia
were significantly less common. Notably, these HCWs had a
comparable demographic and comorbidity profile to those with
positive RT-PCR and the 9 asymptomatic subjects with negative
RT-PCR (Table 1).
No HCWs reported travel from areas with active community
transmission. A resident (HCW6) wearing a surgical mask
observed a suggestive case in the emergency department 3 days
before symptom onset (March 8), who did not fulfill testing
criteria at the time (travel from endemic area). A consultant
(HCW4) had a short, unprotected contact in the week preceding
the outbreak with an inpatient from another department who
was later found to have COVID-19. Of note, 7/14 of infected
HCWs had a common link to our rheumatological procedures
unit, having spent the most hours there over the previous
2 weeks. Nonetheless, the remaining RT-PCR-positive HCWs
had minimal exposure to this facility, and 2 rheumatologists
(HCW18/21), who spent more than 10 h/week in the unit,
tested negative. Finally, all but 10 HCWs (5 RT-PCR-positive,
5 RT-PCR-negative) were present, unprotected, in a 2.5-h
departmental meeting (March 10) addressing the local response
to the pandemic. At the time, only 1 HCW (HCW7) had
symptoms (mild rhinorrhea).
Immunological Response
After a median (IQR) of 45 (40.5–48.5) days following
symptom onset (or the first RT-PCR test for asymptomatic
subjects), 32 HCWs had an assessment of the serological
response (Figure 2). A positive IgM and IgG index (>1.0
AU/mL) was seen in, respectively, 2/14 (14.3%) and 13/14
(92.9%) of the confirmed RT-PCR-positive cases and none
of the symptomatic/asymptomatic RT-PCR-negative subjects
(Figures 2A,B). Both tests had a 96.9% agreement in case
classification (Kappa coefficient 0.936). Assessment timing was
similar for the HCWs with borderline positive IgM (HCW 11/12,
1.10–1.18 AU/mL) or IgG (HCW 12/14, 1.10 AU/mL) compared
to other RT-PCR-positive subjects. In addition, HCW10 had an
IgG index below the positive threshold, despite 2 positive RT-
PCR tests, no immunosuppression, and comparable evaluation
timing and clinical course.
Within the RT-PCR-positive group, considerable variation
was seen in the antibody response (Figure 2B). Notably, subjects
over 50 years old had a higher mean IgG index (14.5 ± 7.7
AU/mL) than younger individuals (5.0 ± 4.4 AU/mL, p =
0.012; Figure 2C). Although the numbers are small, the 3 older
HCWs (HCW 8/11/13) who had an IgG index above 10 AU/mL
experienced a more severe disease course with high fever and
cough, and 2 of them had raised D-dimers, fibrinogen, and CRP.
In contrast, the remaining older HCW (HCW 7) had a mild
course with limited rhinorrhea and gastrointestinal symptoms
and developed a lower IgG index (4.99 AU/mL). Nevertheless,
a positive trend was observed in the correlation between age and
IgG index (Pearson r = 0.53, p = 0.051; Figure 2D). No other
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TABLE 1 | Demographic and clinical characteristics of study participants.
Overall (n = 34) SARS-CoV-2 RT-PCR test results and symptoms p-value
Positive (n = 14) Negative, symptoms Negative, no symptoms
(n = 11) (n = 9)
Age, years (range) 41 ± 12 (26–66) 40 ± 14 (26–62) 40 ± 8 (28–52) 44 ± 15 (27–66) 0.759
Age ≥ 60 years, n (%) 4 (11.8) 2 (14.3) 0 2 (22.2) 0.286
Female, n (%) 23 (67.7) 10 (71.4) 8 (72.7) 5 (55.6) 0.723
Comorbidities, n (%) 20 (58.8) 8 (57.1) 6 (54.6) 6 (66.7) 0.849
Arterial hypertension 5 (14.7) 3 (21.4) 0 2 (22.2) 0.279
Cardiac disease 3 (8.8) 2 (14.3) 0 1 (11.1) 0.601
Diabetes mellitus 2 (5.9) 2 (14.3) 0 0 0.324
Obesity 3 (8.8) 2 (14.3) 1 (9.1) 0 0.768
COPD/asthma 3 (8.8) 1 (7.1) 2 (18.2) 0 0.464
Chronic rhinosinusitis 4 (11.8) 1 (7.1) 2 (18.2) 1 (11.1) 0.806
IMID 6 (17.7) 3 (21.4) 1 (9.1) 2 (22.2) 0.732
Cancer history 2 (5.9) 0 1 (9.1) 1 (11.1) 0.241
Smoking history (ever) 9 (26.5) 4 (28.6) 2 (18.2) 3 (33.3) 0.790
Concomitant therapy, n (%) 5 (14.7) 3 (21.4) 0 2 (22.2) 0.279
ACEi/ARB 5 (14.7) 3 (21.4) 0 2 (22.2) 0.279
NSAIDs 1 (2.9) 0 1 (9.1) 0 0.588
DMARDs 3 (8.8) 1 (7.1) 1 (9.1) 1 (12.5) 1.000
COVID-19 symptoms, n (%)/duration, days 25 (73.5)/24 ± 19 14 (100)/28 ± 18 11 (100)/20 ± 20 0 –
Fever 11 (32.4)/6 ± 8 9 (64.3)/7 ± 9 2 (18.2)/2 ± 1 – 0.042
Cough 15 (44.1)/25 ± 19 9 (64.3)/25 ±14 6 (54.6)/26 ± 26 – 0.622
Dyspnea 3 (8.8)/3 ± 31 2 (14.3)/14 ±10 1 (9.1)/66 1.000
Chest tightness 4 (11.8)/17 ± 16 3 (21.4)/22 ±16 1 (9.1)/4 – 0.603
Malaise 10 (29.4)/15 ± 14 9 (64.3)/16 ± 15 1 (9.1)/6 – 0.012
Fatigue 12 (35.3)/25 ± 21 10 (71.4)/24 ± 21 2 (18.2)/27 ± 25 – 0.015
Headache 11 (32.4)/16 ± 18 10 (71.4)/17 ± 19 1 (9.1)/5 – 0.004
Rhinorrhea 14 (41.2)/18 ± 16 9 (64.3)/24 ± 17 5 (45.5)/7 ± 3 – 0.435
Sore throat 16 (47.1)/7 ± 7 7 (50.0)/9 ± 9 9 (81.8) 5 ± 3 – 0.208
Anosmia 9 (26.5)/15 ± 13 8 (57.1)/16 ± 13 1 (9.1)/6 – 0.033
Dysgeusia 8 (23.5)/12 ± 7 8 (57.1)/12 ± 7 0 – 0.003
Arthralgia 1 (2.9)/25 1 (7.4)/25 0 – 1.000
Myalgia 11 (32.4)/14 ± 17 8 (57.1)/16 ± 20 3 (27.3)/8 ± 9 – 0.004
Abdominal pain 2 (5.9)/3 ± 1 0 2 (18.2)/3 ± 1 – 0.183
Nausea/vomiting/diarrhea 7 (20.6)/11 ± 11 5 (35.7)/13 ± 12 2 (18.2)/5 ± 0 – 0.407
Dizziness 3 (8.8)/9 ± 6 2 (14.3)/10 ± 8 1 (9.1)/8 – 1.000
Disease severity, n (%)
Mild 22 (64.7) 11 (78.6) 11 (100) – 0.230
Moderate 3 (8.8) 3 (21.4) 0
Severe 0 0 0
Hospitalization 0 0 0 – –
Treatment, n (%)/duration, days
None/supportive 27 (79.4) 7 (50) 11 (100) 9 (100) –
Hydroxychloroquine 7 (20.6)/9 ± 3 7 (50)/9 ± 3 0 0
Azithromycin 4 (11.8)/5 ± 0 4 (28.6)/5 ± 0 0 0
Complications, n (%) 1 (2.9) 1 (7.4) 0 0 –
Symptom resolution, n (%) 23 (92) 12 (85.7) 11 (100) – –
Secondary transmission, n (%) 7 (20.6) 7 (50) – – –
Days to 2 negative tests (range) 31 ± 10 (15–51) 31 ± 10 (15–51) – – –
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-II receptor blockers; chronic obstructive pulmonary disease; DMARDs, disease-modifying anti-rheumatic drugs; IMID,
immune-mediated inflammatory disease; NSAIDs, non-steroidal anti-inflammatory drugs. Continuous values represented as mean ± SD.
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FIGURE 1 | Evolution of symptoms and RT-PCR test results of healthcare workers with confirmed or suspected COVID-19. Each row represents a healthcare worker
(HCW) followed over time (columns). Results of reverse transcription polymerase-chain reaction (RT-PCR) are indicated as positive (
⊕
), negative (—) or indeterminate
(±). Mild symptoms include symptoms other than fever, cough, and dyspnea as referred to in the text and Table 1.
clinical factor was associated with antibody response, including
sex; treatment; or presence/duration of fever, cough, or dyspnea.
Secondary Transmission to Patients With
RMDs
A total of 617 patients were identified as having had a potential
risky contact, 561 (91%) of whom were contacted by telephone
and screened for COVID-19 symptoms starting within the
14-day window (Figure 3). We identified 8 (1.3% of total)
female patients (mean age 66.8 ± 14.9 years) who developed
symptoms compatible with COVID-19 (Table 2). Six patients
had a diagnosis of an inflammatory RMD; 3 were treated with
conventional synthetic disease-modifying antirheumatic drugs
(csDMARDs) and glucocorticoids and 2 with biologic DMARDs
(bDMARDs). All contacts took place within the same 2 days
(March 9 and 11), all but one were with a confirmed infected
HCW, and patients denied additional suspicious contacts.
Contact tracing for Patient 1 within the department confirmed
it to be limited to a symptomatic physician with negative
RT-PCR and serology (HCW24). Importantly, in 7/8 cases,
the HCW was asymptomatic at the time of contact, and 1
patient (Patient 6) had a consultation with a physician (HCW7)
presenting only mild serous rhinorrhea. Of note, 5/8 contacts
were in the context of diagnostic (ultrasound) or therapeutic
procedures (mesotherapy), which involved prolonged close
physician–patient contact.
Patients developed symptoms on average 4.3 ± 2.1 days
(range 2–9) after the contact. Half reported fever, 88% had
cough, and only 1 patient reported dyspnea. General and upper
airway symptoms were common, including anosmia (50%)
and dysgeusia (63%). Nasopharyngeal swabs were performed
in 6/8 cases (8.8 ± 3.1 days post-symptom onset), 2 of
which were positive for SARS-CoV-2, and 1 was inconclusive.
Two patients were not tested due to difficulty in reaching
health authorities or personal choice (self-isolation). Patients
with negative/unavailable tests still had suggestive COVID-
19 symptoms.
All but one patient had a mild-to-moderate course and were
clinically recovered after an average of 24.8± 5.9 days. A 90-year-
old woman with giant cell arteritis and relevant cardiovascular
comorbidities, exposed to long-term methotrexate and low-
dose glucocorticoids, was hospitalized after 6 days of fever and
3 days of worsening chest pain and dyspnea. She required
oxygen therapy, received a combination of hydroxychloroquine
(400 mg/day) and lopinavir/ritonavir (800/200 mg/day), and
was discharged after 10 days. Importantly, none of the patients
experienced a flare of the baseline RMD.
DISCUSSION
Our study provides important lessons on the vulnerability and
impact of a COVID-19 outbreak within a large rheumatology
department at a time when universal surgical mask use was
not recommended. Over a single week, 41% of HCWs were
confirmed to be infected by SARS-CoV-2, and an additional 32%
developed mostly overlapping symptoms. Although we could not
detect the index case, the spread of the contagion was fast and
occurred when almost all HCWs were asymptomatic or exhibited
only minor symptoms, easily dismissed or attributed to another
concurrent viral disease. These findings are in accordance with
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FIGURE 2 | Immunological response to SARS-CoV-2 infection among healthcare workers. (A) Percentage of healthcare workers (HCWs) with a positive
immunological response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, defined as an IgM or IgG index equal or above 1.0 AU/mL.
Analysis differentiated by HCW group, depending on the presence of COVID-19 symptoms and the result of reverse transcription-polymerase chain reaction
(RT-PCR). N = 32 (RT-PCR+, N = 14; RT-PCR– symptoms, n = 10; RT-PCR– no symptoms, n = 8). *None of the HCWs in this group developed anti-SARS-CoV-2
antibodies (i.e., frequency = 0%) (B) Index of anti-SARS-CoV-2 antibodies (IgG and IgM) according to RT-PCR result and COVID-19 symptoms. Dashed line
represents positive threshold (1.0 AU/mL). Error bars represent mean with standard deviation. (C) Distribution of anti-SARS-CoV-2 IgG antibodies in RT-PCR+ HCWs,
according to age group (below or above 50 years old). Error bars represent mean with standard deviation. *p = 0.012. (D) Correlation between age and
anti-SARS-CoV-2 IgG antibodies in RT-PCR+ HCWs. r, Pearson correlation coefficient.
current concerns around the presymptomatic or asymptomatic
transmission of SARS-CoV-2 among HCWs and patients (9, 14–
16). As viral shedding and infectiousness are higher in the 2–
3 days prior to symptom onset and rapidly decrease thereafter
(26, 27), a high proportion of contagion occurs during the
presymptomatic stage (18, 26). In addition, asymptomatic (17,
22, 28, 29) and mild disease forms with limited upper respiratory
symptoms are now widely recognized (23, 27) and may escape
vigilance protocols, more focused on the presence of fever, cough,
and dyspnea. This was certainly the case in our cluster, in which
testing of all HCWs of the department, whether symptomatic
or not, was vital to identify cases and contain the outbreak.
Therefore, in healthcare settings, continuous mask use, social
distancing, and mild-symptom monitoring should be adopted
among HCWs, together with proactive testing strategies, to
account for potential pre/asymptomatic carriers (15).
The outbreak had a profound repercussion in the clinical
activity of the department. Infected subjects had protracted
symptoms and were away from work for around 1 month.
In addition, prolonged viral shedding (up to 51 days) led
to frequent RT-PCR repetition (median 5 tests) until cure
was confirmed, consuming substantial resources. Our findings
regarding viral RNA swab positivity are longer than previously
reported (20, 30–32), which may be related to differences in
specimen collection (double naso- and oropharyngeal swab in
our study), study population, or disease severity. Interestingly,
similar nasopharyngeal viral loads in patients with mild and
severe disease have been reported (30) although a separate study
concluded otherwise (33). Moreover, some data suggest that a
positive RT-PCR does not denote the actual presence of viable
virus, especially after the first week (27, 34). However, this is
not yet fully established, and we would, therefore, advocate for 2
consecutive negative tests before HCWs return to work. In effect,
21/59 (36%) of repeat tests were positive, and in 5 instances,
a positive or indeterminate test followed a first negative result,
highlighting the difficulties of interpretation (34).
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FIGURE 3 | Flow chart of RMD patient screening for symptoms suggestive of COVID-19. Patients with possible contacts with healthcare workers with positive reverse
transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory coronavirus 2 (SARS-CoV-2) in the period of March 2–13, 2020, were contacted by
telephone and screened for COVID-19 symptoms starting within the subsequent 14 days. See Methods for details.
All HCWs had a mild-to-moderate disease course, and there
were no major complications. We believe the positive outcome
of the cohort is mainly related to the young mean age with only
2 HCWs older than 60 years. Alternatively, a lower initial viral
exposure load could also explain an overall milder phenotype
(33). Nevertheless, most of the infected HCWs (93%) developed
an immune response, which tended to be more robust in older
individuals. This, in turn, may be secondary to a more severe
clinical course, known to be strongly associated with age (20, 35).
A possible explanation for this finding could be a higher peak
viral load, also previously shown to be positively correlated with
age (30). Indeed, we highlight that 2/13 (15.4%) IgG-positive
HCWs, both under 30 years old and with a very mild disease
course, had borderline IgG indexes. Nevertheless, other factors,
such as T-cell–mediated immunity (36–38), may be involved,
as 1 HCW in the 40- to 50-year-old range who had cough
and 2 positive RT-PCR tests did not develop IgG antibodies 47
days post-symptom onset. Concordance between serology and
RT-PCR was otherwise excellent, confirming previous reports
(20, 30, 31). Although it cannot be completely excluded, this
suggests there were no false-negative RT-PCR results, including
in symptomatic HCWs.
Finally, secondary transmission to a minority of patients did
occur from 4 HCWs who were asymptomatic (75%) or had mild
upper airway symptoms (25%),mostly in close proximity contact.
As one of the confirmed cases only contacted with HCW 24
(negative RT-PCR and serology), we cannot exclude undisclosed
community contagion or nosocomial transmission through
fomites (39). Also, we admit that patients with negative/missing
RT-PCR could be false negative or undiagnosed cases, possibly
due to a larger interval between symptom onset and testing.
Of note, all contacts occurred when preventive measures had
already been adopted, and 80% of face-to-face clinical activity
had been deferred, which might explain the low number of
infected patients. We admit the possibility that contagion
could have followed the opposite route (pre/asymptomatic
patients to HCWs) although symptom timing does suggest
otherwise. Notwithstanding the advanced age and long-term use
of cs/bDMARDs and low-dose glucocorticoids in half the cases,
all patients had a favorable outcome. This is in accordance with
recent data that did not demonstrate an increased incidence of
severe disease in RMD patients (40, 41).
Our study has some limitations. Due to its real-life nature,
clinical assessment and RT-PCR timing were clinically based
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TABLE 2 | Clinical features of RMD patients with confirmed or suspected COVID-19.
Patient ID 1 2 3 4 5 6 7 8





APS Sarcoidosis RA PsA Rotator cuff
tendinopathy
Disease duration 11.1 y 10.1 y 7.7 mo 2.2 y 13.7 y 4.7 mo 15.7 y 11.2 mo
Disease activity Low Remission Remission No events Remission Low Moderate Low/mild












Smoking status Past Past Past Active Never Never Never Never










DFZ (9) PDN (5) No No No PDN (7.5) No No
NSAIDs No No Nimesulide No Acemetacin No Acemetacin No
ACEi/ARB Ramipril No No Perindopril Ramipril No No Lisinopril
HCW contact (#) RT-PCR– (24) RT-PCR+ (1) RT-PCR+ (1) RT-PCR+ (14) RT-PCR+ (1) RT-PCR+ (7) RT-PCR+ (1) RT-PCR+ (1)
Contact date 9/3/2020 11/3/2020 9/3/2020 9/3/2020 9/3/2020 11/3/2020 11/3/2020 11/3/2020








Contact duration 15min 10min 30min 30min 10min 30min 10min 10 min
Days from contact to
symptom onset













(1) Mal, Ftg, Hdx,

























Positive (13) Positive (4) Inconclusive (11)
Negative (21)
Negative (9) N/A Negative (8) N/A Negative (8)
Symptom duration 14 20 30 21 31 25 29 28
Hospitalization (days) No Yes (10) No No No No No No
ICU admission N/A No N/A N/A N/A N/A N/A N/A
Complications No No No No No No No No
Targeted treatment No HCQ,
LOP+RIT
No No No No No No
Treatment changes ↓ DFZ 6mg Suspended
MTX
No No ↑ NSAID freq No No No
Outcome Cure Cure Cure Cure Cure Cure Cure Cure
Days to 2 negative
tests
34 20 N/A N/A N/A N/A N/A N/A
Abd, abdominal pain; ACEi, angiotensin-converting enzyme inhibitors; Ansm, anosmia; APS, antiphospholipid syndrome; ARB, angiotensin-II receptor blockers; Arth, arthralgia;
AZT, azathioprine; Chx, chest pain/tightness; Cgh, cough; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CV,
cerebrovascular; dx, disease; DFZ, deflazacort; Dizz, dizziness/vertigo; DMARDs, disease-modifying anti-rheumatic drugs; Dysg, dysgeusia; Dysp, dyspnoea; Freq, frequency; Ftg,
fatigue; Fv, fever; GCA, giant cell arteritis; GI, gastrointestinal, including nausea, vomiting, diarrhea; HCQ, hydroxychloroquine; HCW, healthcare worker; Hdx, headache; HT, hypertension;
ICU, intensive care unit; IFX, infliximab; ILD, interstitial lung disease; LEF, leflunomide; LOP, lopinavir; Mal, malaise; mo, months; MTX, methotrexate; N/A, not applicable; NSAIDs,
non-steroidal anti-inflammatory drugs; OP, osteoporosis; PDN, prednisolone; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RIT, ritonavir; Rhin, rhinorrhea; RMD, rheumatic and
musculoskeletal diseases; RT-PCR, reverse transcription-polymerase chain reaction; SLE, systemic lupus erythematosus; Thr, sore throat; US, ultrasound; w, weeks; y, years.
and differed slightly between subjects. As computed tomography
was not performed, we cannot completely exclude COVID-19
pneumonia. Two fellows could not be tested for serology upon
finishing their clerkship. Also, 9% of the identified RMD patients
could not be reached.
In conclusion, we demonstrate that a COVID-19
outbreak can occur among HCWs and rheumatic patients,
spreading over the presymptomatic stage and evolving with
mild-to-moderate symptoms, delayed viral shedding, and
prolonged recovery.
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